Related Experiment Video
Updated: Mar 6, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
[Biomarkers of prostate cancer sensitivity to the Sendai virus]
A A Belova1, A O Sosnovtseva1,2, A V Lipatova1,3
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
Abstract:
Metastatic prostate cancer is often associated with either primary or intractable castration-resistant prostate cancer (CRPC), thus justifying the search for entirely new ways of treatment. Oncolytic viruses are able to selectively induce the death of tumor cells without affecting normal cells. A murine Sendai virus has potential to be used as an oncolytic agent. However, tumors vary in their sensitivity to different viruses, prompting us to attempt to identify corresponding biomarkers that reflect the interaction of cancer cells and the virus. Here, we show that the sensitivity of primary prostatic adenocarcinoma cell lines to Sendai virus strain (SeVM) vary substantially. Using quantitative PCR, we evaluated expression levels of genes that encode RIG-1-like and Toll-like receptors (TLRs) in cell lines and showed that the levels of mRNAs that encode TLR3 and TLR7 correlate with a degree of sensitivity of the cells to Sendai virus. The lines with lower levels of TLR3 and TLR7 expression are more sensitive to the virus.
Insights
Researchers explored biomarkers for oncolytic virus therapy in prostate cancer. Lower expression of Toll-like receptors (TLR3 and TLR7) correlated with increased sensitivity to Sendai virus (SeVM) in cancer cells.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Metastatic prostate cancer, including castration-resistant prostate cancer (CRPC), necessitates novel therapeutic strategies.
- Oncolytic viruses offer selective tumor cell lysis, sparing normal tissues.
- Tumor sensitivity to oncolytic viruses varies, indicating a need for predictive biomarkers.
Purpose of the Study:
- To investigate biomarkers predicting sensitivity of prostate cancer cells to oncolytic viruses.
- To evaluate the correlation between specific receptor expression and Sendai virus (SeVM) efficacy.
Main Methods:
- Assessed sensitivity of primary prostatic adenocarcinoma cell lines to SeVM.
- Utilized quantitative PCR to measure mRNA expression levels of RIG-1-like and Toll-like receptors (TLRs).
- Correlated TLR expression with cellular sensitivity to SeVM.
Main Results:
- Prostate cancer cell lines exhibited significant variation in sensitivity to SeVM.
- mRNA levels of Toll-like receptor 3 (TLR3) and Toll-like receptor 7 (TLR7) were quantified.
- Lower expression of TLR3 and TLR7 mRNA correlated with higher sensitivity to SeVM.
Conclusions:
- TLR3 and TLR7 expression levels serve as potential biomarkers for predicting oncolytic virus therapy response in prostate cancer.
- Understanding these receptor-virus interactions can guide the development of targeted oncolytic virotherapy strategies.
